Stuttering
27
6
6
12
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.7%
1 terminated out of 27 trials
92.3%
+5.8% vs benchmark
4%
1 trials in Phase 3/4
0%
0 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (27)
Organization and Development of Motor Cortical Circuits for Speech Production in Stuttering
The Development of Stuttering in Young Children
Using Non-invasive Brain Stimulation to Explore Potential Treatments to Reduce Speech Errors in Adults Who Stutter
Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter
Stuttering and Neuromodulation
Network Connectivity and Temporal Processing in Adolescents Who Stutter
Speech Processing in Stuttering
Genetic Linkage Studies of Stuttering
Shaping Motor Neural Functioning of Developmental Stuttering to Improve Fluency
Exploring the Nature, Assessment and Treatment of Stuttering
Computerized Based Analysis for Detection and Severity Assessment of Stuttering
Assessment of Stuttering Severity in Adults and Adolescences in Conversational and Narrative Contexts
How Stuttering and Gestures Influence the Intelligibility of Individuals With Down Syndrome
IBSR Intervention for Adults Who Stutter
Providing Speech Therapy Awareness in Private Schools
Central Mechanisms in Speech Motor Control Studied With H215O PET
Characteristics of Idiopathic Familial Speech Disorders
Study of Brain Activity During Speech Production and Speech Perception
Enhancing Speech Fluency With Non-invasive Brain Stimulation in Developmental Stuttering
A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering